Zymeworks (ZYME): Director bought ~$1.47M
EcoR1 Capital, Director at Zymeworks, bought ~$1.47M of Zymeworks shares.
- ~$1.47M
- Approx. value · 102K sh @ $14.49
- 14.8M
- Holds after · shares reported
- Traded
- Dec 27, 2024
- Filed
- Dec 27, 2024
What stands out in this filing
- The purchase added 0.7% to the shares this insider held before it; the filing reports 14,822,590 shares, held indirectly afterwards.
- 101,659 shares at an average of $14.49 each, as reported on the form.
- The first open-market purchase by this insider in 0 months.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 19, 2024InsiderDirector purchased ~$4.04M of ZYME shares in the open market
- Dec 20, 2024InsiderDirector purchased ~$9.92M of ZYME shares in the open market
- Dec 23, 2024InsiderDirector purchased ~$3.58M of ZYME shares in the open market
- Dec 24, 2024InsiderDirector purchased ~$169K of ZYME shares in the open market
- Dec 26, 2024InsiderDirector purchased ~$240K of ZYME shares in the open market
- Dec 27, 2024 · this disclosureInsiderDirector purchased ~$1.47M of ZYME shares in the open market
What came next
- Dec 30, 2024InsiderDirector purchased ~$853K of ZYME shares in the open market
- Dec 31, 2024InsiderDirector purchased ~$2.13M of ZYME shares in the open market
- Jan 2, 2025InsiderDirector purchased ~$2.33M of ZYME shares in the open market
- Jan 6, 2025Insider · 3 peopleInsiders: 5 sales (~$1.3M)
- Jan 8, 2025InsiderDirector purchased ~$296K of ZYME shares in the open market
- Jan 10, 2025InsiderDirector purchased ~$2.68M of ZYME shares in the open market
- Jan 13, 2025InsiderDirector purchased ~$993K of ZYME shares in the open market
- Jan 14, 2025InsiderDirector purchased ~$739K of ZYME shares in the open market
- Jan 15, 2025InsiderDirector purchased ~$547K of ZYME shares in the open market
- Jan 16, 2025InsiderDirector purchased ~$1.69M of ZYME shares in the open market
- Jan 17, 2025InsiderDirector purchased ~$274K of ZYME shares in the open market
- Mar 11, 2025InsiderDirector purchased ~$3.69M of ZYME shares in the open market
- Mar 12, 2025InsiderDirector purchased ~$3.59M of ZYME shares in the open market
- Mar 13, 2025InsiderDirector purchased ~$5.85M of ZYME shares in the open market
- Mar 17, 2025InsiderDirector purchased ~$688K of ZYME shares in the open market
- Mar 18, 2025InsiderDirector purchased ~$1.44M of ZYME shares in the open market
- Mar 19, 2025InsiderDirector purchased ~$737K of ZYME shares in the open market
- Mar 20, 2025InsiderDirector purchased ~$950K of ZYME shares in the open market
- Mar 21, 2025InsiderDirector purchased ~$397K of ZYME shares in the open market
- Mar 24, 2025InsiderDirector purchased ~$297K of ZYME shares in the open market
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Zymeworks
For Zymeworks, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ZYME page.
Other recent filings by EcoR1 Capital, LLC, Director
- SEC Form 4 at Anaptysbio (ANAB)Nov 18, 2026
- SEC Form 4 at Anaptysbio (ANAB)Nov 18, 2026
- SEC Form 4 at Anaptysbio (ANAB)Nov 18, 2026
- SEC Form 4 at Atara Biotherapeutics (ATRA)May 11, 2026
- SEC Form 4 at Zymeworks (ZYME)May 19, 2025
The full history of EcoR1 Capital, LLC, Director is on the profile page.
How this filing works
Explore the data
Common questions
Which Zymeworks (ZYME) insider traded, and how much?
EcoR1 Capital, Director at Zymeworks, bought ~$1.47M of Zymeworks shares. 102K shares at $14.49, open market.
When did it happen, and when was it made public?
Traded: Dec 27, 2024. Filed: Dec 27, 2024.
What stands out in this filing?
The purchase added 0.7% to the shares this insider held before it; the filing reports 14,822,590 shares, held indirectly afterwards. 101,659 shares at an average of $14.49 each, as reported on the form. The first open-market purchase by this insider in 0 months.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Zymeworks recently?
For Zymeworks, OQRO holds 8 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the ZYME page.
Does this mean ZYME stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Zymeworks
- SEC Form 144Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 4Nov 16, 2026
- SEC Form 144Nov 13, 2026
Everything OQRO holds on this company is on its ZYME page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
